Inclusion Criteria

Inclusion Criteria for iNHL:

- The patient has biopsy-confirmed diagnosis of indolent B-cell NHL documented as
relapsed or refractory iNHL (following rituximab-based therapy).

- The patient has one of the following types of indolent B-cell lymphoma:

- follicular lymphoma grade 1, 2, or 3A

- marginal zone lymphoma

- lymphoplasmacytic lymphoma

- small lymphocytic lymphoma

- The patient has adequate haematologic function (unless abnormalities are related to
lymphoma involvement of the bone marrow or hypersplenism caused by lymphoma).

Inclusion Criteria for CLL:

- The patient has previously confirmed (according to WHO criteria) untreated
symptomatic chronic B-cell lymphocytic leukemia Binet Stage B or Binet Stage C or Rai
stage II to IV in need of medical treatment.

- The patient has an Eastern Cooperative Oncology Group (ECOG) performance status of
0-2.

Exclusion Criteria:

- The patient has participated in a clinical study <30 days prior to the Screening
Visit.

- The patient has one or more of the following conditions:

- active transformed lymphoma

- any history of central nervous system or leptomeningeal lymphoma

- an active malignancy other than the target cancer within the past 5 years

- human immunodeficiency virus

- The patient is, in the investigator's opinion, unlikely to comply with the protocol
or is unsuitable for any reason.

Other inclusion and exclusion criteria may apply.